Introduction {#Sec1}
============

*Streptococcus pneumoniae* is one of the leading causes of morbidity and mortality worldwide^[@CR1]--[@CR3]^. *S. pneumoniae* causes a range of diseases including pneumonia, meningitis, septicemia and otitis media, and produces a range of virulence factors including the toxin pneumolysin, pneumococcal surface protein A and pilus^[@CR2],[@CR4]--[@CR6]^. The current *S. pneumoniae* vaccines target the capsular polysaccharide, but cover only a subset of the 97 known capsular serotypes. Differences in serotype distribution between developed and developing countries, and serotype replacement in response to widespread use of the vaccines, are reducing the overall impact of the vaccines on the burden of pneumococcal disease^[@CR1],[@CR3]^.

Expression of the pneumococcal Pilus-1, composed of three proteins RrgA, RrgB and RrgC, has been linked to pneumococcal meningitis in mouse infection models^[@CR5]--[@CR7]^. Pilus-1 was found to be required for the bacteria to breach the blood brain barrier^[@CR5]^. The Pilus-1 protein complex consists of RrgB as the shaft protein, with RrgA as the tip adhesin and RrgC, which serves as a pilus anchor at the cell surface^[@CR6]--[@CR8]^. The *S. pneumoniae* Pilus-1 protein complex has been proposed as a novel vaccine target^[@CR9],[@CR10]^. The RrgA and RrgB proteins were found to produce cross-protecting antibodies that led to blocking of adherence of *S. pneumoniae* to cells in culture and resulted in the opsonophagocytosis of *S. pneumoniae* ^[@CR9],[@CR11]^. RrgA is also involved in regulation of the host immune response to *S. pneumoniae* by binding to both MAC-1 (complement receptor 3, CD11b/CD18)^[@CR12]^ and Toll-like receptor 2^[@CR13]^. RrgA has also been shown to interact directly with cultured epithelial cells and extracellular matrix components including fibronectin and collagen^[@CR10]^.

All of the known proteins that interact with RrgA are glycoproteins, indicating a potential role of the oligosaccharides in the interactions. In this study we aim to identify glycan targets of the Pilus-1 protein complex of *S. pneumoniae*.

Results {#Sec2}
=======

RrgA, RrgB and RrgC proteins bind glycans {#Sec3}
-----------------------------------------

Glycan array analysis of the three Pilus-1 proteins from *S. pneumoniae* TIGR4 and RrgA from strain SPEC6B revealed differential glycan recognition between the four proteins tested. *S. pneumoniae* TIGR4 RrgB bound the least number of glycans, with only an α-mannobiose recognized (Table [1](#Tab1){ref-type="table"} and Dataset [S1](#MOESM1){ref-type="media"}). RrgA from *S. pneumoniae* TIGR4 and RrgA from *S. pneumoniae* SPEC6B bound to a set of overlapping glycans including terminal galactose structures with both α and β linkages, glucose/maltose-related structures and blood group A (7 K and 392) and blood group H(O) (7 A) antigens (Table [1](#Tab1){ref-type="table"} and Dataset [S1](#MOESM1){ref-type="media"}). No interactions with terminal galactose structures were observed when galactose was directly linked to glucose. *S. pneumoniae* SPEC6B RrgA also had binding to β-linked mannose and β-linked N-acetylglucosamine structures not bound by the TIGR4 RrgA. RrgC bound to structures that are the same or very similar to RrgA from TIGR4 with additional recognition of blood group B antigen (483), Lewis B (496) and hyaluronic acid (14I) (Table [1](#Tab1){ref-type="table"} and Dataset [S1](#MOESM1){ref-type="media"}).Table 1Glycans bound by Rrg proteins in glycan array analysis.No.StructureRrgA T4RrgA SPEC6BRrgB T4RrgC T4**MONOSACCHARIDES**3Galβ-sp31587 ± 308369 ± 188108 ± 88.92165 ± 45014Glc*N*(Gc)β-sp4157 ± 1712112 ± 110−37.5 ± 63.5191.3 ± 12418Manβ-sp4166.3 ± 1982532 ± 436−113.5 ± 68.8600.5 ± 65022Glc*N*Acβ-sp41140 ± 30255.5 ± 413227 ± 19057.5 ± 184**Terminal Galactose**76Galα1-3Galβ-sp31918.3 ± 154142 ± 120−67.3 ± 347284.5 ± 18080Galα1-3Glc*N*Acβ-sp390.75 ± 196270.5 ± 37940.5 ± 3881627 ± 12288Galβ1-3Gal*N*Acβ-sp31013 ± 1011251 ± 87.015.3 ± 2041402 ± 20489Galβ1-3Gal*N*Acα-sp31098 ± 2772495 ± 322−7 ± 2661033 ± 29594Galβ1-4Galβ-sp41218 ± 458186 ± 24873.5 ± 247374.3 ± 190100Galβ1-6Galβ-sp42197 ± 4861027 ± 149144.8 ± 1143443.5 ± 523220Galα1-3Galβ1-4Glcβ-sp2142.9 ± 201151.3 ± 15263.75 ± 95.51283 ± 310222Galα1-3Galβ1-4Glc*N*Acβ-sp399.0 ± 237150.5 ± 162−107.8 ± 3053108 ± 641373Galα1-3Galβ1-4Glc*N*Acβ1-3Galβ-sp31802.5 ± 2761270 ± 19462.3 ± 1482374 ± 839381Galβ1-3Glc*N*Acβ1-6Galβ1-4Glc*N*Acβ-sp21985.4 ± 2802600 ± 232−72.3 ± 166567.0 ± 259383Galβ1-4Glc*N*Acβ1-3Galβ1-4Glcβ-sp2126.0 ± 279−510.3 ± 557157 ± 4141799 ± 160489Galβ1-4Glc*N*Acβ1-3(Glc*N*Acβ1-6)Galβ1-4Glc*N*Ac-sp278.25 ± 96.3437.3 ± 435188 ± 1221107 ± 142501Galβ1-3Gal*N*Acβ1-3Galα1-4Galβ1-4Glcβ-sp4116.0 ± 1661012 ± 77.557.3 ± 185187.0 ± 155504(A-GN-M)~2~-3,6-M-GN-GNβ-sp4197.8 ± 201105.3 ± 76.3124174.5 ± 78.51906 ± 1801 GGalβ1-3Glc*N*Acβ1-3Galβ1-4Glc4605 ± 1711613 ± 15014 ± 165606.1 ± 7382 GGalβ1-3Glc*N*Acβ1-3Galβ1-4Glc*N*Acβ1-6(Galβ1-3Glc*N*Acβ1-3)Galβ1-4Glc1344 ± 5832655 ± 197−127 ± 128301.3 ± 300**Terminal N-Acetylgalactosamine**2 FGal*N*Acα1-3Galβ1-4Glc1221.5 ± 2042988 ± 200144.3 ± 246595.6 ± 614**Fucosylated**392Fucα1-2(Gal*N*Acα1-3)Galβ1-3Gal*N*Acα-sp31366 ± 2962274 ± 208140.6 ± 1652350 ± 329480Fucα1-2Galβ1-3Glc*N*Acβ1-3Galβ1-4Glc*N*Acβ-sp2315.25 ± 272.0421122.5 ± 399264 ± 42721.5 ± 227483Fucα1-3(Fucα1-2 (Galα1-3)Galβ1-4)Glc*N*Acβ-sp3327.3 ± 438−17.5 ± 311170.5 ± 2301178 ± 258496Fucα1-2Galβ1-3(Fucα1-4)Glc*N*Acβ1-3Galβ1-4Glcβ-sp4274.5 ± 331286 ± 10538.5 ± 75.51192 ± 322538Le^x^1-6′(Le^c^1-3′)Lac-sp41261.5 ± 346118.3 ± 20693.6 ± 114131.3 ± 204539LacNAc1-6′(Le^d^1-3′)Lac-sp4206.8 ± 2101393 ± 16059.3 ± 247−49.0 ± 6027AFucα1-2Galβ1-3Glc*N*Acβ1-3Galβ1-4Glc1897.3 ± 2952619 ± 95.1−41.8 ± 91.7130.3 ± 2837KGal*N*Acα1-3(Fucα1-2)Gal1159.0 ± 1622302 ± 14969.8 ± 176472.8 ± 5878ASO~3~-3Galβ1-3(Fucα1-4)Glc*N*Ac918.5 ± 84.61638 ± 272101.5 ± 14229.0 ± 1128JFucα1-2Galβ1-4(Fucα1-3)Glc*N*Acβ1-3(Fucα1-2)Galβ1-4Glc1692.3 ± 305138 ± 338−120.8 ± 125245.3 ± 2658KGalβ1-4(Fucα1-3)Glc*N*Acβ1-6(Galβ1-4Glc*N*Acβ1-3)Galβ1-4Glc170.0 ± 1777622 ± 13172 ± 141807.5 ± 791**Mannose**120Manα1-3Manβ-sp418.0 ± 40690 ± 2221332 ± 27541.1 ± 54**Terminal N-Acetylglucosamine**117Glc*N*Acβ1-4Glc*N*Acβ-sp4145.6 ± 2385714 ± 1240−73 ± 113226.5 ± 179118Glc*N*Acβ1-6Gal*N*Acα-sp31322.5 ± 336−61 ± 175−56.3 ± 99.6122.3 ± 31253Glc*N*Acβ1-6Galβ1-4Glc*N*Acβ-sp254.75 ± 21225.8 ± 60.1−160 ± 74.91641 ± 117505(GN-M)~2~-3,6-M-GN-GNβ-sp4244.5 ± 1832695 ± 35128.0 ± 214106.3 ± 180**Glucose**112Glcβ1-6Glcβ-sp41284.8 ± 4451863 ± 44.6−154.5 ± 176506.5 ± 418390(Glcα1-4)~4~β-sp4930.5 ± 94.71700 ± 31189.3 ± 413187.3 ± 154**High molecular weight Carageenan and Glycoaminoglycans (GAGS)**14IHA 1600000 da 2.5 mg/ml985 ± 884187.8 ± 164422.5 ± 6981270 ± 147Values are global background subtracted. Red indicates binding. Binding is determined by positive interaction in three replicate array experiments. Positive interactions are determined by a background subtracted fluorescence value significantly above background subtracted fluorescence of negative control spots (average background fluorescence from 20 spots + 3 standard deviations).

Surface Plasmon Resonance analysis of RrgA and glycans identified by array analysis {#Sec4}
-----------------------------------------------------------------------------------

To validate the glycan array results and to determine the dissociation equilibrium constant (K~D~) of the interactions, surface plasmon resonance was performed between free oligosaccharides and captured RrgA proteins (Table [2](#Tab2){ref-type="table"}). The highest affinity (smallest K~D~) interaction was between RrgA proteins from both *S. pneumoniae* TIGR4 and SPEC6B and the H trisaccharide type 3/4 (Table [2](#Tab2){ref-type="table"}).Table 2Surface plasmon resonance results for RrgA proteins and glycans^a^.OligosaccharideRrgA TIGR4RrgA SPEC6BBlood group A tri916.5 nM ± 66.41.4 μM ± 0.29Blood group A type3/4870.7 nM ± 286643.6 nM ± 157Blood group H type 3/489.4 nM ± 16358.1 nM ± 51Lewis X434.0 nM ± 118363.3 nM ± 107Lacto-N-tetraose1.03 μM ± 0.05868.6 nM ± 454maltobiose1.16 μM ± 0.09964.0 nM ± 226cellobiose1.48 μM ± 251582.8 nM ± 155chitobiose409.3 nM ± 160426.2 nM ± 144lactoseNCDINCDI^a^Data are dissociation equilibrium constants (K~D~) of the interactions between free oligosaccharides and captured RrgA proteins; NCDI: no concentration-dependent interaction detected.

Inhibition of adherence of RrgA-expressing *S. pneumoniae* TIGR4 using free oligosaccharides {#Sec5}
--------------------------------------------------------------------------------------------

*S. pneumoniae* TIGR4 and *S. pneumoniae* TIGR4Δ*rrgA* were tested for adherence differences using A549 human lung carcinoma and Detroit 562 pharyngeal carcinoma cell lines. These cell lines are representative of the two most important sites for colonization/infection of humans by *S. pneumoniae*. *S. pneumoniae* TIGR4Δ*rrgA* was significantly less adherent to both cell lines, with RrgA contributing to around 50% of the adherence of *S. pneumoniae* TIGR4 to A549 cells and 70% of the adherence to Detroit 562 cells (Table [3](#Tab3){ref-type="table"}).Table 3Adherence of TIGR4 vs TIGR4Δ*rrgA*.A549 adherence (% TIGR4 ± SEM)^*a*^Detroit 562 (% TIGR4 ± SEM)^*b*^TIGR4100 ± 5.4100 ± 19.8TIGR4Δ*rrgA*52.7 ± 3.927.1 ± 7.4Significance*P* \< 0.001*P* \< 0.01Data are the average of two separate experiments consisting of 4 individual wells (experiment 1) and 5 individual wells (experiment 2) (n = 9). ^a^100% = 1.97 × 10^7^ CFU per well. ^b^100% = 8.70 × 10^6^ CFU per well.

The Detroit 562 and A549 cell lines were examined for the presence of RrgA target glycans using lectin array analysis (see Dataset [S2](#MOESM2){ref-type="media"}). Lectins recognizing terminal β-linked galactose were observed for both cells. The A549 cells were recognized by the lectins AAA and RSL, both of which recognize structures containing α1-2 linked fucose, while the Detroit 562 cells did not (Dataset [S2](#MOESM2){ref-type="media"}). Lectins with α1-2 linked fucose specificity recognize blood group antigens, particularly the H (O) blood group antigens.

Adherence of *S. pneumoniae* TIGR4 to A549 cells was then re-examined using four of the oligosaccharides identified through the glycan array analysis as competitive inhibitors. The blood group H type 3/4 trisaccharide provided the best blocking of *S. pneumoniae* TIGR4 adherence, with 67.7% inhibition (Table [4](#Tab4){ref-type="table"}; *P* \< 0.001). In addition, maltose, cellobiose and blood group A tetrasaccharide all reduced adherence by around 56% (Table [4](#Tab4){ref-type="table"}; *P* \< 0.001 in all cases). Interestingly, the residual A549 adherence observed for TIGR4Δ*rrgA* (approximately 50% relative to wild type TIGR4) could also be competitively inhibited by a further 30--46% by cellobiose and blood group A tetrasaccharide and H trisaccharide (Table [4](#Tab4){ref-type="table"}; *P* \< 0.001).Table 4Effect of glycans on adherence of TIGR4 to A549 cells.Strain/glycanA549 adherence (% control ± SEM)^*a*^Significance vs untreatedTIGR4^*a*^100 ± 9.2---TIGR4 + 200 μM lactose85.5 ± 11.0Not significantTIGR4 + 200 μM maltose43.7 ± 9.2*P* \< 0.001TIGR4 + 200 μM cellobiose44.6 ± 3.1*P* \< 0.001TIGR4 + 200 μM BGA type 3/444.0 ± 2.5*P* \< 0.001TIGR4 + 200 μM BGH type3/432.3 ± 2.7*P* \< 0.001TIGR4Δ*rrgA* ^*b*^100 ± 3.9---TIGR4Δ*rrgA* + 200 μM cellobiose62.4 ± 4.2*P* \< 0.001TIGR4Δ*rrgA* + 200 μM BGA type 3/469.6 ± 2.1*P* \< 0.001TIGR4Δ*rrgA* + 200 μM BGH type3/453.5 ± 1.6*P* \< 0.001Data are the average from four individual wells performed as replicates (n = 4). ^*a*^100% = 3.50 × 10^7^ CFU per well. ^*b*^100% = 1.97 × 10^7^ CFU per well. BGA: Blood group A, BGH: Blood group H.

Discussion {#Sec6}
==========

Adherence to host tissues is the first step in disease and host glycoconjugates are a common target for numerous bacterial adhesins^[@CR14]--[@CR16]^, including pili/fimbriae^[@CR17],[@CR18]^. Pilus-1 of *S. pneumoniae* has been shown to interact with Toll-like receptor 2 and MAC-1^[@CR12],[@CR13]^ and epithelial cells and ECM components^[@CR10]^, all of which are glycosylated.

The glycan array analysis of RrgA from *S. pneumoniae* TIGR4 and SPEC6B identified a cluster of oligosaccharide binding that was consistent between the two proteins. These proteins have previously been shown to bind to both cells and ECM components equally, indicating recognition of uncapped β-linked galactose. Binding of *S. pneumoniae* RrgA to β-linked galactose and blood group A glycan is consistent with interactions between *S. pneumoniae* and a wide variety of cell surfaces in the human host.

The array binding was investigated further using surface plasmon resonance analysis. Binding to blood group antigens, β-galactose, maltose, cellobiose and GlcNAc were confirmed through SPR analysis, with the highest affinity interaction observed occurring between RrgA from TIGR4 with the H-type 3/4 oligosaccharide (Table [2](#Tab2){ref-type="table"}). As observed in the array experiment, no concentration dependent interaction was observed using SPR for terminal galactose with underlying glucose (lactose; Table [2](#Tab2){ref-type="table"}). The SPR analysis found high affinity binding between RrgA and Lewis X (K~D~ \< 500 nM; Table [2](#Tab2){ref-type="table"}).

The significance of these interactions in terms of interaction with host surfaces was further confirmed by competitive inhibition of TIGR4 adherence to A549 cells by exogenous maltose, cellobiose, blood group A type 3/4 and blood group H type 3/4 oligosaccharides. Interestingly, although RrgA is thought to be the most important component of the Pilus-1 structure in terms of mediating adherence, the residual A549 adherence exhibited by TIGR4Δ*rrgA* could be inhibited further, albeit to a slightly lesser extent, by the three exogenous oligosaccharides that were most effective against TIGR4. There are multiple *S. pneumoniae* surface proteins that have been shown to have a role in adherence to host epithelial cells, most notably CbpA, which is known to bind to cell surface glycoconjugates^[@CR19]^, indicating that the residual binding observed in the TIGR4Δ*rrgA* is likely to be another adhesin.

The direct interaction between RrgA and Lewis X was not seen on the array, but Lewis X was a terminal group on several of the larger fucosylated structures identified (Table [1](#Tab1){ref-type="table"}; 8 J and 8 K). This may indicate that the binding of Lewis X requires a specific presentation that is available in solution, but not available on the array except as a part of a larger structure. Lewis X is a member of the Lewis system histo-blood group antigens, which were originally identified on RBCs where they are acquired from the plasma as glycolipids^[@CR20]^ and is expressed on most cell types but is over-expressed by human tumor cells from various sites^[@CR21]^.

*S. pneumoniae* is a host-adapted pathogen that infects humans so it is unexpected to observe the binding of the Rrg proteins to many non-human and non-mammalian glycans. Rrg proteins recognised maltose and cellulose saccharides, repeating units of glucose typically produced by plants, algae and some bacteria^[@CR22]^. This interaction may allow *S. pneumoniae* to interact with other bacterial species either directly or to the matrix of bacteria in biofilm communities.

RrgC and RrgA also bound to the non-human terminal α1-3-linked galactose structures. RrgC bound four of the 11 terminal α1-3-linked galactose structures present on the array, while RrgA only bound 1-2 terminal α1-3-linked galactose structures on the array (Table [1](#Tab1){ref-type="table"}). This binding does not correlate with the host adapted nature of *S. pneumoniae* with α1-3-linked galactose widely expressed in non-human mammals but not in humans. The expression of α1-3-linked galactose is only observed in humans that produce blood group B antigens, structures not recognised on the array by the Rrg proteins.

The Pilus-1 complex of *S. pneumoniae* is known to be an important mediator of adherence of *S. pneumoniae* to host epithelial cells. This binding appears to be glycan related, as RrgA was found to have lectin activity, recognising a range of common host cell surface glycans. All three proteins that make up the Pilus-1 complex recognise glycans as recombinant soluble proteins. Thus, we have identified three new lectins produced by *S. pneumoniae*, with the pilius tip protein RrgA directly involved in interactions between pathogen and host.

Materials and Methods {#Sec7}
=====================

Cloning, expression and purification of Rrg proteins {#Sec8}
----------------------------------------------------

Genes were cloned into pET protein expression vectors and proteins were expressed and purified as previously described^[@CR10]^.

Glycan Array {#Sec9}
------------

Glycan array slides were printed using SuperEpoxy 3 activated substrates as previously described^[@CR23]^ using an ArrayIt Spotbot Extreme 3 contact printer with solid metal pins. The Glycan array binding experiments were performed and analysed as previously described^[@CR16]^. Briefly 1 μg of protein in 1xPBS containing 1 mM MgCl~2~ and 1 mM CaCl~2~ was pre-complexed with mouse anti-His antibody (Cell signaling), Alexa555 rabbit anti-mouse IgG and Alexa555 goat anti-rabbit IgG and allowed to bind to a pre-blocked (1% bovine serum albumin in PBS) for 15 minutes. Slides were washed three times for 2 minutes in 1xPBS, dried by centrifugation and scanned and analysed using the Scan Array Express software package (Perkin Elmer) and Microsoft Excel for statistical analysis (Student's unpaired *t-*test of fluorescence of background spots vs fluorescence of glycan printed spots).

Surface Plasmon Resonance analysis {#Sec10}
----------------------------------

The interactions between the Rrg proteins and test glycans were analysed using surface plasmon resonance (SPR) using a Biacore T100 system as described Shewell *et al*.^[@CR16]^ with the following modifications. Proteins were immobilised onto a CM5 chip at pH 4.5, flow rate of 10 µL/min for 420 seconds with an ethanolamine blank flow cell as a control. Glycans were tested between 160 nM and 100 µM. All data was double reference subtracted.

Mutagenesis of *rrgA* in *S. pneumoniae* TIGR4 {#Sec11}
----------------------------------------------

The *rrgA* gene in TIGR4 was deleted in-frame and replaced with an erythromycin resistance cassette (*erm*) by direct transformation with a linear DNA fragment constructed by overlap-extension PCR, essentially as previously described^[@CR24]^. This involved using primer pairs rrgAF/rrgAermR and rrgAermF/rrgAR to amplify 5′ and 3′ regions flanking *rrgA* from TIGR4 template DNA, and J214/J215 to amplify *erm* from pVA838 (Table [5](#Tab5){ref-type="table"}). Primers included overlapping sequences such that the three PCR products could be fused in a second round of PCR using primer pair rrgAF/rrgAR Erythromycin-resistant transformants were screened by PCR for deletion of *rrgA*, confirmed by DNA sequencing and designated TIGR4Δ*rrgA*.Table 5Oligonucleotide primers.PrimerSequence 5′-3′rrgAFCAGAAACTAGAGAGCAGAAGTGrrgARCTGACGGCTAGTTAGTAATGCrrgAermRTTGTTCATGTAATCACTCCTTCTATTCATAGAACAAGTTAATCCTTCrrgAermFCGGGAGGAAATAATTCTATGAGAGTGTAGAAATGATATCTATGTTCJ214GAAGGAGTGATTACATGAACAAJ215CTCATAGAATTATTTCCTCCCG

Competitive inhibition of adherence of *S. pneumoniae* with free glycans {#Sec12}
------------------------------------------------------------------------

Adherence assays on A549 (human type II pneumocyte) and Detroit 562 (human nasopharyngeal carcinoma) cells were carried out as previously described^[@CR25]^. A549 and Detroit 562 cells were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco), or a 1:1 mix of DMEM and Ham's F-12 Nutrient Mixture (Gibco), respectively, supplemented in both cases with 5% fetal bovine serum, 2 mM L-glutamine, 50 IU of penicillin and 50 μg/ml streptomycin. Confluent monolayers in 24-well plates were washed with PBS and infected with pneumococci (approximately 5 × 10^5^ CFU per well) in a 1:1 mixture of the respective culture medium (without antibiotics) and C + Y medium, pH 7.4^[@CR23]^. Plates were centrifuged at 500 × *g* for 5 min, and then incubated at 37 °C in 5% CO~2~ for 2.5 h. Monolayers were washed 3 times in PBS, and adherent bacteria were released by treatment with 100 μl trypsin/EDTA, followed by 400 μl 0.025% Triton X-100. Lysates were serially diluted and plated on blood agar to enumerate adherent bacteria. Total adherence (mean ± SEM for 4-9 replicates) was expressed as a percentage of that for TIGR4 (or TIGR4Δ*rrgA* where appropriate) without additives. For inhibition assays, free oligosaccharides were used at a final concentration of 200 μM (\>100 × K~D~) throughout the adherence assay. Data were analysed using Student's un-paired *t*-test (two-tailed).

Lectin array analysis of Detroit 562 and A549 cells {#Sec13}
---------------------------------------------------

The two cells lines used for adherence assays, A549 and Detroit 562, were analysed for cell surface glycans using lectin arrays. Lectin arrays were printed using an ArrayJet Argus Marathon Inkjet Bio-Printing System on Arrayit SME3 substrates. The lectins are immobilized to the epoxy activated substrate through non-specific amine coupling through free amines on the lectin proteins and the epoxide groups on the glass. Arrays were neutralized and performed as previously described^[@CR26]^, with the exception that Bodipy 558/568 succinimidyl ester (Thermo Scientific) was used in place of CFDA-SE. Briefly, cells were collected and washed in 1xPBS prior to being labelled for 30 minutes at 37 °C with Bodipy 558/568 succinimidyl ester. Cells were washed three times with PBS and resuspended in PBS containing 1 mM MgCl~2~ and 1 mM CaCl~2~ at 10^7^ cells/mL and 300 µL was applied to the array in a 125 µL frame without a coverslip. Cells were allowed to interact with the lectins on the array for 30 minutes and then the slides were washed three times with PBS, fixed in 4% formaldehyde and dried by centrifugation. Slides were scanned on an Innopsys InnoScan 1100AL to acquire the data of which lectins bound to the cells and analysed using Innopsys Mapix data acquisition and analysis software and Microsoft Excel for statistical analysis (Student's unpaired *t*-test of fluorescence of background spots vs fluorescence of lectin printed spots).
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